HSBC Starts Teva Pharma (TEVA) at Buy, 'innovative medicine division to become a driver of growth'

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/17/2026

1. GNK
2. AZN
3. HIVE
4. SPY
5. GSAT

6. DSX
7. ALH
8. SERV
9. RDDT
10. CRGO

Get Alerts TEVA Hot Sheet

Price: $36.77 --0%

Rating Summary:
17 Buy, 22 Hold, 1 Sell

Rating Trend:

Up

Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19

Join SI Premium – FREE

(Updated - December 18, 2023 4:37 AM EST)

HSBC analyst Rajesh Kumar initiates coverage on Teva Pharma (NYSE: TEVA) with a Buy rating and a price target of $13.00.

The analyst comments "As the new management team sets a clear strategy, we see Teva as lowly rated, with potential for its innovative medicine division to become a driver of growth and margin improvement. We initiate coverage on the stock with a Buy rating."

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $9.98 yesterday.

Create E-mail Alert Related Categories

Analyst Comments, New Coverage

Related Entities

HSBC

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!